Cognitio Neuropharm AB

Cognitio Neuropharm AB is a dynamic biotechnology research company dedicated to pioneering innovative solutions for neurocognitive diseases. Specializing in the research of cures for nervous system disorders that lead to cognitive decline, Cognitio Neuropharm AB leverages cutting-edge science to improve patient outcomes.

Based in Stockholm, Cognitio Neuropharm AB focuses on developing small molecule drug compounds that enhance the synchronization of electrical activity in major neuronal classes. This approach aims to stabilize neuronal network activity, which is crucial for sensory information processing, learning, and memory. Cognitio Neuropharm AB's work has identified a novel target for treating Alzheimer’s disease and related disorders, validated through successful treatment trials in animal models and human stem cells.

Cognitio Neuropharm AB is committed to advancing the field of neurodegenerative brain disease treatment. We invite the manager of Cognitio Neuropharm AB to create a customized and exclusive company showcase and product listing on our platform, further enhancing your company's visibility and commercial potential.